This post was published on ZYX Buy Change Alert.
MNTA has an average price of $11.31. As of this writing it is trading at $19.05. The stock has jumped on a court invalidating TEVA patent on a MS drug Copaxone. This was part of the original thesis to buy MNTA. MYL is the other beneficiary.
The stock previously hit the target zone but not the upper band of the target zone until yesterday. It appears that many subscribers are still holding. Consider taking profits on the position, if still holding, in the zone of $18.43 to $20.88 and exit the position. As a reminder, if trying to wait for a higher price to exit, please be sure to put protective stops right under the low band of the new target zone.
Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007. Please click here and scroll down to see the table of all trades. These trades have been scrutinized in real-time by thousands of subscribers across the globe. This provides easy verification of performance for newcomers to this site. Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog. When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table. There are very nice gains on this trade but since the entry trade was not posted here in real-time, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.
You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.